Xofluza (Baloxavir Marboxil) Dosing and Clinical Guidance
Baloxavir marboxil (Xofluza) is administered as a single weight-based oral dose for treatment of acute uncomplicated influenza in patients ≥5 years of age within 48 hours of symptom onset, or for post-exposure prophylaxis within 48 hours of contact with an influenza-infected individual. 1
Dosing by Weight
For patients ≥5 years of age:
- <20 kg: 2 mg/kg as single dose (oral suspension)
- 20 kg to <80 kg: 40 mg as single dose
- ≥80 kg: 80 mg as single dose
The medication may be taken with or without food, though you must avoid coadministration with dairy products, calcium-fortified beverages, polyvalent cation-containing laxatives, antacids, or oral supplements (calcium, iron, magnesium, selenium, zinc) as these significantly reduce absorption. 1, 2
Indications
Treatment: Acute uncomplicated influenza in patients ≥5 years who have been symptomatic for ≤48 hours, whether otherwise healthy or at high risk of complications. 1
Post-exposure prophylaxis: Following contact with an influenza-infected individual, administered within 48 hours of exposure. 1, 2
Contraindications
Absolute contraindication: History of hypersensitivity to baloxavir marboxil or any ingredient, including anaphylaxis, angioedema, urticaria, or erythema multiforme. 1
Critical Precautions and Warnings
Age Restriction (<5 Years)
Baloxavir is NOT indicated for children <5 years of age due to significantly increased treatment-emergent resistance in this population. In clinical trials, resistance rates were markedly higher in children <5 years compared to older patients, with treatment-emergent PA protein variants (I38T/M/F substitutions) conferring reduced susceptibility. 1, 2
Resistance Development
Treatment-emergent resistance occurs in approximately 5-10% of treated patients, with PA protein variants (I38T/M/N substitutions) emerging during therapy. 3, 4, 5 This is higher than neuraminidase inhibitor resistance rates. The clinical significance of these variants includes potential for human-to-human transmission. 5, 6
Bacterial Superinfection Risk
Baloxavir does not prevent secondary bacterial infections. Serious bacterial infections may begin with influenza-like symptoms or occur as complications. Maintain vigilance for bacterial superinfection and treat appropriately. 1
Drug Interactions
Avoid live attenuated influenza vaccine (LAIV) within 2 weeks before or 48 hours after baloxavir administration, as antiviral activity may interfere with vaccine replication and reduce immunogenicity. 1
Clinical Efficacy Context
Baloxavir demonstrates similar symptom reduction to oseltamivir (median time to symptom alleviation ~54 hours vs ~80 hours for placebo), but offers superior viral load reduction at 24 hours post-dose compared to both oseltamivir and placebo. 3, 4, 5 The single-dose regimen provides a compliance advantage over 5-day oseltamivir courses. 7
For influenza B specifically, baloxavir showed better efficacy than oseltamivir in randomized controlled trials. 7
However, in children <6 years, symptom recurrence after day 4 occurred in 54.5% and fever recurrence in 50% in post-hoc analyses, raising concerns about durability of response in very young children. 7
AAP Positioning
The American Academy of Pediatrics considers oseltamivir the preferred agent for both treatment and post-exposure prophylaxis of influenza A and B. 2 Baloxavir is positioned as an alternative when compliance is a concern or when there is poor tolerance of multi-dose regimens. 7
Baloxavir should be considered particularly for:
- Patients with compliance concerns regarding 5-day oseltamivir courses
- Influenza B infections (where it may have superior efficacy)
- Situations where rapid viral load reduction is prioritized
- When oseltamivir is unavailable or not tolerated
Common Adverse Events
Adults/adolescents: Diarrhea (3%), bronchitis (3%), nausea (2%), sinusitis (2%), headache (1%) 1
Pediatric patients (5 to <12 years): Vomiting (5%), diarrhea (5%) 2, 1
The safety profile is comparable to placebo and oseltamivir. 3, 4
Renal/Hepatic Impairment
No dosage adjustment is required for mild-to-moderate hepatic or renal impairment. 8, 9 Severe impairment has not been adequately studied.
Transmission Prevention
Recent evidence demonstrates baloxavir reduces transmission to household contacts by 29% (adjusted incidence 9.5% vs 13.4% with placebo by day 5, P=0.01), supporting its use in outbreak settings and for post-exposure prophylaxis. 6, 10